<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clopidogrel: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clopidogrel: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clopidogrel: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8921" href="/d/html/8921.html" rel="external">see "Clopidogrel: Drug information"</a> and <a class="drug drug_patient" data-topicid="12311" href="/d/html/12311.html" rel="external">see "Clopidogrel: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F10072956"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP-450) system, principally CYP2C19. Clopidogrel at recommended doses forms less of the active metabolite and has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 genes (termed “CYP2C19 poor metabolizers”). Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y<sub>12</sub> inhibitor in patients identified as CYP2C19 poor metabolizers.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F153626"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Plavix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866401"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Clopidogrel;</li>
<li>AG-Clopidogrel;</li>
<li>APO-Clopidogrel;</li>
<li>Auro-Clopidogrel;</li>
<li>BIO-Clopidogrel;</li>
<li>DOM-Clopidogrel;</li>
<li>JAMP-Clopidogrel;</li>
<li>M-Clopidogrel;</li>
<li>Mar-Clopidogrel;</li>
<li>MINT-Clopidogrel;</li>
<li>NRA-Clopidogrel;</li>
<li>Plavix;</li>
<li>PMS-Clopidogrel;</li>
<li>PRIVA-Clopidogrel [DSC];</li>
<li>RIVA-Clopidogrel;</li>
<li>SANDOZ Clopidogrel [DSC];</li>
<li>TARO-Clopidogrel;</li>
<li>TEVA-Clopidogrel</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1006665"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiplatelet Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462411"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72305440-84cf-444d-bd2e-a15f1970317b">Antiplatelet effect</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Antiplatelet effect:</b> Limited data available: Oral: 0.2 mg/kg/dose once daily. A double-blind, placebo-controlled trial of 906 patients (n=461 neonates; n=445 infants ≤3 months) with cyanotic congenital heart disease surgically treated with a systemic-to-pulmonary artery shunt did not demonstrate a clinical benefit compared to placebo. Concomitant aspirin was used in 88% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CLARINET.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CLARINET.1'])">Ref</a></span>). In another trial, 0.2 mg/kg/dose once daily was found to achieve a mean inhibition of platelet aggregation similar to a standard adult dose; <b>Note:</b> This study (PICOLO Trial) included 73 evaluable patients (n=34 neonates [with exclusion of patients with weight &lt;2 kg and GA &lt;35 weeks]; n=39 infants ≤24 months) with a systemic-to-pulmonary artery shunt, intracardiac or intravascular stent, Kawasaki disease, or arterial graft; 79% of patients received concomitant aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18195173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18195173'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812492"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72305440-84cf-444d-bd2e-a15f1970317b">Antiplatelet effect</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiplatelet effect:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤24 months: In the PICOLO trial, a dose of 0.2 mg/kg/dose once daily was found to achieve a mean inhibition of platelet aggregation similar to adults receiving the adult recommended dose; <b>Note:</b> This study included pediatric patients with a systemic-to-pulmonary artery shunt, intracardiac or intravascular stent, Kawasaki disease, or arterial graft; 79% of patients received concomitant aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-18195173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-18195173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;2 years and Adolescents: Initial dose: 1 mg/kg once daily; in general, do not exceed adult dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-16291359','lexi-content-ref-16527995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-16291359','lexi-content-ref-16527995'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>CYP2C19 poor metabolizers (ie, CYP2C19*2 or *3 carriers):</b> Specific pediatric recommendations are lacking; based on experience in adult patients, routine genetic testing is not recommended in patients treated with clopidogrel undergoing percutaneous coronary intervention; testing may be considered to identify poor metabolizers who would be at risk for poor response while receiving clopidogrel and if identified, these patients may be considered for an alternative P2Y12 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22064601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22064601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729668"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; use with caution. Based on adult data, no dosage adjustment is required; in adults, GFR stage 5 (ie, end-stage renal disease or an eGFR &lt;15 mL/minute) is associated with higher residual platelet reactivity with maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22425260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22425260'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F52729669"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; in adults, no dosage adjustment is necessary.</p></div>
<div class="block doa drugH1Div" id="F153630"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8921" href="/d/html/8921.html" rel="external">see "Clopidogrel: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>In patients who require concomitant therapeutic anticoagulation, antiplatelet selection and/or duration of therapy may differ in order to balance risks for thrombosis and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine platelet-function testing or genetic testing for CYP2C19 polymorphisms is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27036918','lexi-content-ref-23698643','lexi-content-ref-31202949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27036918','lexi-content-ref-23698643','lexi-content-ref-31202949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ST-segment elevation myocardial infarction: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Regardless of the reperfusion strategy, administer clopidogrel in combination with a parenteral anticoagulant and aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>If using fibrinolytic therapy for reperfusion: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Age ≤75 years: <b>Oral:</b> Initial loading dose: 300 mg once at the time of diagnosis; followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-15758000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-15758000'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Age &gt;75 years: <b>Oral:</b> 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Patient requires percutaneous coronary intervention following fibrinolytic therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Fibrinolytic administered <b>with</b> a clopidogrel 300 mg loading dose: <b>Oral:</b> Continue 75 mg once daily (do not administer an additional loading dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Fibrinolytic administered <b>≤24 hours ago</b>
<b>without</b> a loading dose of clopidogrel:<b> Oral:</b> Initial: 300 mg once prior to percutaneous coronary intervention (PCI); followed by 75 mg once daily after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Fibrinolytic administered &gt;<b>24 hours ago</b>
<b>without</b> a loading dose of clopidogrel: <b>Oral:</b> Initial: 600 mg once prior to PCI; followed by 75 mg once daily after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>If using percutaneous coronary intervention for reperfusion (alternative agent) (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Ticagrelor or prasugrel may be preferred over clopidogrel unless there is high risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846','lexi-content-ref-17982182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846','lexi-content-ref-17982182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 600 mg once as early as possible before PCI; followed by 75 mg once daily after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19796737','lexi-content-ref-20817281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19796737','lexi-content-ref-20817281'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>If no planned reperfusion strategy (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Some experts prefer ticagrelor over clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 300 mg once at the time of diagnosis; followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Duration of therapy: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Preferred approach: Clopidogrel plus aspirin (dual antiplatelet therapy [DAPT]) should be continued for ≥12 months unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue clopidogrel and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25399658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25399658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: Clopidogrel in combination with aspirin (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue clopidogrel monotherapy. When clopidogrel is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ST-segment elevation acute coronary syndromes: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Regardless of the management strategy, administer clopidogrel in combination with a parenteral anticoagulant and aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>If using an ischemia-guided approach (medical management) (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Some experts prefer ticagrelor over clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 600 mg once at the time of diagnosis; followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249585'])">Ref</a></span>). Some experts prefer an initial dose of 600 mg unless there is high risk for bleeding, in which case, an initial dose of 300 mg is reasonable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>If using an invasive approach (reperfusion using percutaneous coronary intervention) (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Ticagrelor or prasugrel may be preferred over clopidogrel unless there is high risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846','lexi-content-ref-17982182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846','lexi-content-ref-17982182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 600 mg once as early as possible before PCI; followed by 75 mg once daily after PCI. If coronary angiography is planned soon after diagnosis, it is reasonable to delay the initial loading dose until after coronary anatomy is known (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Duration of therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Preferred approach: Clopidogrel plus aspirin (DAPT) should be continued for ≥12 months unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue clopidogrel and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25399658','lexi-content-ref-11520521','lexi-content-ref-11519503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25399658','lexi-content-ref-11520521','lexi-content-ref-11519503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: Clopidogrel in combination with aspirin (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue clopidogrel monotherapy. When clopidogrel is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5a987cb-ccff-4ac0-a154-864ff35e02a8">Percutaneous coronary intervention for stable ischemic heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Percutaneous</b>
<b> coronary intervention for stable ischemic heart disease (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer clopidogrel in combination with a parenteral anticoagulant and aspirin for patients who undergo PCI with stenting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 600 mg once, administered ≥2 hours before PCI, ideally ≥24 hours before PCI; followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Duration of therapy</b>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bare metal stent implantation: Dual antiplatelet therapy (DAPT) for at least 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>). Some experts recommend at least 6 months when feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.3'])">Ref</a></span>). Assess bleeding and ischemic risks to determine if patient should receive a longer duration of DAPT. Upon completion of DAPT, continue aspirin or clopidogrel monotherapy for treatment of stable ischemic heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug eluting stent implantation: DAPT for at least 6 months. Assess bleeding and ischemic risks to determine if patient should receive a longer duration of DAPT. Upon completion of DAPT, continue aspirin or clopidogrel monotherapy for treatment of stable ischemic heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: DAPT for 1 to 3 months, then discontinue aspirin and continue clopidogrel monotherapy for up to 12 months or longer. If clopidogrel is discontinued, restart aspirin for treatment of stable ischemic heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Cutlip.3','lexi-content-ref-31237645','lexi-content-ref-33202084','lexi-content-ref-31237644'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f0c4dfb-f5d8-4ac1-bc40-73546ebcb89c">Carotid artery atherosclerosis, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carotid artery atherosclerosis, symptomatic (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who are intolerant of aspirin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315275','lexi-content-ref-Cucchiara.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315275','lexi-content-ref-Cucchiara.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4279d92-24ed-42de-bfa6-a1d30d71a104">Carotid artery stenting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carotid artery stenting (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Percutaneous approach:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Initiation ≥48 hours before procedure: <b>Oral:</b> 75 mg <b>twice daily</b> in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initiation &lt;48 hours before procedure: <b>Oral:</b> 450 mg once at least 4 hours before procedure in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i>
<b>Oral:</b> 75 mg <b>once daily</b> in combination with aspirin for at least 4 weeks; then discontinue clopidogrel and continue aspirin indefinitely thereafter. In patients with history of neck irradiation, some experts recommend continuing clopidogrel plus aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21282493','lexi-content-ref-20505173','lexi-content-ref-Jim.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21282493','lexi-content-ref-20505173','lexi-content-ref-Jim.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transcarotid approach:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Initiation ≥72 hours before procedure: <b>Oral:</b> 75 mg once daily in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26506270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initiation &lt;72 hours before procedure: <b>Oral:</b> 450 mg once at least 4 hours before procedure in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26506270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i>
<b>Oral:</b> 75 mg once daily in combination with aspirin for at least 4 weeks; then discontinue clopidogrel and continue aspirin indefinitely thereafter. In patients with history of neck irradiation, some experts recommend continuing clopidogrel plus aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20505173','lexi-content-ref-Jim.2','lexi-content-ref-26506270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20505173','lexi-content-ref-Jim.2','lexi-content-ref-26506270'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3894f364-f488-4544-b8fe-1fc5fa6a9ee7">Coronary artery bypass graft surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery bypass graft surgery (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Aspirin-allergic or aspirin-intolerant patients:</b></i>
<b>Oral:</b> 75 mg once daily; continue indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302'])">Ref</a></span>). Some experts recommend a loading dose of 300 mg administered 6 hours after surgery, followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Levin.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Levin.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Following off-pump </b>
<b>coronary artery bypass graft </b>
<b>
<b>surgery</b>:</b></i>
<b>Oral:</b> 75 mg once daily in combination with aspirin for 1 year, then discontinue clopidogrel and continue aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302','lexi-content-ref-23488578','lexi-content-ref-22942294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302','lexi-content-ref-23488578','lexi-content-ref-22942294'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients with acute coronary syndrome followed by coronary artery bypass graft surgery:</b></i>
<b>Oral:</b> 75 mg once daily in combination with aspirin for 1 year, then discontinue clopidogrel and continue aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25679302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25679302'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ade487d-45f5-4924-b1e0-a51400ed80ed">Ischemic stroke/transient ischemic attack</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Isch</b>
<b>emic stroke/transient ischemic attack</b></p>
<p style="text-indent:0em;">
<b>Note: </b>In patients who receive IV thrombolytic therapy, antiplatelet therapy is generally delayed for at least 24 hours, but administered as soon as possible thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-Filho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-Filho.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Due to intracranial large artery atherosclerosis (50% to 99%), secondary prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Avoid dual antiplatelet therapy (DAPT) in patients with hemorrhagic transformation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Filho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Filho.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Short-term (90 days) DAPT with concomitant aspirin in patients with recent (≤30 days) stroke or transient ischemic attack (TIA) due to 70% to 99% stenosis of an intracranial large artery: </i>75 mg once daily for 90 days in combination with aspirin; when clopidogrel is stopped, continue aspirin indefinitely. Some experts recommend a loading dose of 300 to 600 mg once, followed by 75 mg once daily for 90 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Turan.2021','lexi-content-ref-23803136','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Turan.2021','lexi-content-ref-23803136','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Short-term (21 days) DAPT with concomitant aspirin in patients with recent (≤30 days) minor stroke or high-risk TIA due to 50% to 69% stenosis of an intracranial large artery</i>: 75 mg once daily for 21 days in combination with aspirin; when clopidogrel is stopped, continue aspirin indefinitely. Some experts recommend a loading dose of 300 to 600 mg once, followed by 75 mg once daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Turan.2021','lexi-content-ref-23803136','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Turan.2021','lexi-content-ref-23803136','lexi-content-ref-Manu.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>D</i></b>
<b>
<i>ue to other noncardioembolic causes (eg, small vessel disease), secondary prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For patients with recent (eg, ≤24 hours) minor stroke or high-risk TIA, may consider short-term (21 to 90 days) DAPT with aspirin in combination with clopidogrel followed by long-term single-agent antiplatelet therapy with aspirin, clopidogrel, or aspirin/ER dipyridamole. Avoid DAPT in patients with hemorrhagic transformation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-Filho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-Filho.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 75 mg once daily indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117'])">Ref</a></span>). <b>Note:</b> When used as a component of DAPT, give 300 to 600 mg once followed by 75 mg once daily in combination with aspirin for 21 to 90 days, followed with single-agent antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117'])">Ref</a></span>). Some experts recommend limiting DAPT to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Filho.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Filho.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4eb6a6c8-7eb5-4596-a5f9-f9418cd27acc">Peripheral atherosclerotic disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral atherosclerotic disease (upper or lower extremity; with or without revascularization)</b>
<b>:</b>
<b>Oral:</b> 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315275','lexi-content-ref-27840333','lexi-content-ref-8918275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315275','lexi-content-ref-27840333','lexi-content-ref-8918275'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3792761-d523-43d2-bcf6-c3b17da7be6c">Stable ischemic heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stable ischemic heart disease (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Aspirin is generally preferred; clopidogrel is an alternative for patients who have a history of GI bleeding or are allergic to aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211','lexi-content-ref-22315274','lexi-content-ref-8918275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211','lexi-content-ref-22315274','lexi-content-ref-8918275'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8054df2a-d7fd-4f65-bd28-8fefe4da7104">Transcatheter aortic valve replacement, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transcatheter <i>aortic</i> valve replacement, thromboprophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Refer to institutional policies and procedures on use of antiplatelet therapy for patients who require therapeutic anticoagulation for a different indication.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg once prior to valve implantation in combination with aspirin, followed by 75 mg once daily; may be used in combination with aspirin for 3 to 6 months depending on the type of valve implanted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28063810','lexi-content-ref-33332150','lexi-content-ref-29121410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28063810','lexi-content-ref-33332150','lexi-content-ref-29121410'])">Ref</a></span>). To minimize risk of bleeding complications, may give aspirin <b>or </b>clopidogrel alone and reserve dual antiplatelet therapy during the first 3 to 6 months for patients at high risk of a thrombotic event; for either strategy, continue aspirin indefinitely after the initial 3 to 6 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32865376','lexi-content-ref-31609071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32865376','lexi-content-ref-31609071'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08d3ea97-d2a3-4544-80cc-c3f0086f39eb">Transcatheter mitral valve repair with MitraClip device, thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transcatheter <i>mitral </i>valve repair with MitraClip device, thromboprophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Patients are generally treated with antithrombotic therapy (antiplatelet or anticoagulant if there is a concurrent indication) for at least 6 months following the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Loading dose:</b> 300 mg once immediately following MitraClip insertion or within 24 hours prior to the procedure; may use as monotherapy or in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance:</b> 75 mg once daily for at least 6 months; may use as monotherapy or in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280640'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between P2Y<sub>12</sub> inhibitors: Note: </b>This provides general guidance on transitioning between P2Y<sub>12</sub> inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transitioning from another P2Y<sub>12</sub> inhibitor to clopidogrel:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Transitioning from prasugrel: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient received prasugrel for ≤5 days: </i>Give a clopidogrel 300 mg loading dose 24 hours after the last dose of prasugrel, followed by 75 mg once daily; some experts do not administer a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient received prasugrel for &gt;5 days: </i>Give clopidogrel 75 mg once daily, starting 24 hours after the last dose of prasugrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23428007','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23428007','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Transitioning from ticagrelor: </i></b>Give a clopidogrel 600 mg loading dose 12 to 24 hours after the last dose of ticagrelor, followed by 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-29526833','lexi-content-ref-Lincoff.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-29526833','lexi-content-ref-Lincoff.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990801"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Patients with chronic kidney disease, especially those with end-stage kidney disease (ESKD), have a higher incidence of high on-treatment platelet reactivity when treated with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22425260','lexi-content-ref-25476742','lexi-content-ref-30909763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22425260','lexi-content-ref-25476742','lexi-content-ref-30909763'])">Ref</a></span>). Monitor for thrombotic complications and consider measuring platelet reactivity in patients at high risk for thrombotic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31202949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31202949'])">Ref</a></span>). Patients with ESKD are also at increased risk for bleeding, with or without antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24318806','lexi-content-ref-25476742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24318806','lexi-content-ref-25476742'])">Ref</a></span>); monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18370553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18370553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT</b>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987998"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F56021613"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel may cause <b>minor hemorrhage</b> or <b>major hemorrhage</b>. In the CURE trial, clopidogrel was associated with significantly more major bleeding, defined as disabling bleeding, intraocular bleeding leading to the loss of vision, or bleeding necessitating the need for a transfusion of at least 2 units of blood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11519503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11519503'])">Ref</a></span>). Bleeding should be suspected if patient becomes hypotensive, even if overt signs of bleeding do not exist. It may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the clopidogrel loading dose or 2 hours of the maintenance dose may be less effective. Other studies suggest that platelet transfusions are ineffective in reversing antiplatelet effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30911446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30911446'])">Ref</a></span>). May result in temporary or permanent discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29740754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29740754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action. Clopidogrel irreversibly binds to the P2Y12 receptor on platelets, which inhibits adenosine diphosphate (ADP)-mediated platelet activation and aggregation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20440227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20440227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; one study found that clopidogrel was associated with increased risk of major bleeding during all time intervals assessed (0 to 6 months, 7 to 12 months, and 13 to 18 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20442361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20442361'])">Ref</a></span>). Other studies suggest that bleeding risk increases after 21 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31238700','lexi-content-ref-31424481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31238700','lexi-content-ref-31424481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥75 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28622955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28622955'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that increase the risk of bleeding (eg, aspirin, direct oral anticoagulants, nonsteroidal anti-inflammatory drugs, warfarin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700620','lexi-content-ref-29538453','lexi-content-ref-33202084','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700620','lexi-content-ref-29538453','lexi-content-ref-33202084','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses of concurrent aspirin (≥200 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14504182','lexi-content-ref-11519503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14504182','lexi-content-ref-11519503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Active peptic ulcer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12940930','lexi-content-ref-23265750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12940930','lexi-content-ref-23265750'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent trauma or surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21166368','lexi-content-ref-23694867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21166368','lexi-content-ref-23694867'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent or recurrent GI bleed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22948933','lexi-content-ref-28622955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22948933','lexi-content-ref-28622955'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use &gt;6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33202084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33202084'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel hypersensitivity may present as immediate (eg, <b>angioedema</b>, <b>urticaria</b>) and delayed reactions. Delayed hypersensitivity reactions range from the more common pruritic <b>maculopapular rash </b>to rare severe cutaneous adverse reactions including <b>drug reaction with eosinophilia and systemic symptoms</b> and <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21939827','lexi-content-ref-28721327','lexi-content-ref-32110414','lexi-content-ref-24739100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21939827','lexi-content-ref-28721327','lexi-content-ref-32110414','lexi-content-ref-24739100'])">Ref</a></span>). Drug discontinuation due to a pruritic rash may occur in up to 1.5% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22111683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22111683'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions: Non–dose-related; immunologic (ie, IgE-mediated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22111683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22111683'])">Ref</a></span>). Delayed hypersensitivity reactions: Non–dose-related; immunologic (ie, likely involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-21939827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-21939827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Onset</i>: Rapid to intermediate; mean onset of maculopapular, pruritic rash is 6 ± 2 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22111683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22111683'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Because of structural similarities, cross-reactivity has been reported among the thienopyridines (clopidogrel, prasugrel, ticlopidine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beavers.1','lexi-content-ref-25653921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beavers.1','lexi-content-ref-25653921'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombotic thrombocytopenic purpura</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>thrombotic thrombocytopenic purpura</b> (TTP) associated with clopidogrel use have been reported and some have resulted in fatalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22091257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22091257'])">Ref</a></span>); however, incidence is rare (0.0001%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19180126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19180126'])">Ref</a></span>). Early signs of TTP are typically skin reactions or neurologic changes (eg, seizure, coma, stroke, headache, blurred vision) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15561695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15561695'])">Ref</a></span>). TTP is typically characterized by thrombocytopenia, hemolytic anemia, kidney failure, and fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22091257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22091257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic or idiosyncratic. The mechanism for TTP is unknown but likely involves microvascular endothelial cell damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26623244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26623244'])">Ref</a></span>). Decreased ADAMTS-13 activity has been noted; although, some patients have normal ADAMTS13 activity, suggesting that the mechanism may not be immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bennett.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bennett.1'])">Ref</a></span>). Another proposed mechanism is that clopidogrel may act as a hapten in patients with preexisting autoimmune disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26684918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26684918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; usually occurs within 2 weeks of initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22091257','lexi-content-ref-23111862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22091257','lexi-content-ref-23111862'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F153598"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As with all drugs that may affect hemostasis, bleeding is associated with clopidogrel. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Hematologic &amp; oncologic: Major hemorrhage (≤4%; major hemorrhage, life-threatening: ≤2%)<span class="lexi-table-link-container"> (<a aria-label="Major Hemorrhage table link" class="lexi-table-link" data-table-id="lexi-content-major-hemorrhage" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-major-hemorrhage')">table 1</a>)</span><span class="table-link" style="display:none;">Major Hemorrhage</span>, minor hemorrhage (4% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Minor Hemorrhage table link" class="lexi-table-link" data-table-id="lexi-content-minor-hemorrhage" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-minor-hemorrhage')">table 2</a>)</span><span class="table-link" style="display:none;">Minor Hemorrhage</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Major Hemorrhage" frame="border" id="lexi-content-major-hemorrhage" rules="all">
<caption style="text-align:center;">
<b>Clopidogrel: Adverse Reaction: Major Hemorrhage</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clopidogrel [+ Aspirin])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (+ Aspirin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clopidogrel [+ Aspirin])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo [+ Aspirin])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,259</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,303</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,259</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,303</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Life-threatening</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22,961</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22,891</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Minor Hemorrhage" frame="border" id="lexi-content-minor-hemorrhage" rules="all">
<caption style="text-align:center;">
<b>Clopidogrel: Adverse Reaction: Minor Hemorrhage</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clopidogrel [+ Aspirin])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (+ Aspirin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clopidogrel [+ Aspirin])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo [+ Aspirin])</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,259</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,303</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22,961</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22,891</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hemorrhagic stroke</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, vasculitis (Shetty 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Ulman 2014), bullous rash, eczema, erythema multiforme, erythematous rash (Cheema 2011), exfoliative dermatitis, lichen planus, lichenoid eruption (Dogra 2003), maculopapular rash (Cheema 2011), pruritus (Cheema 2011), pustular psoriasis (Meissner 2006), Stevens-Johnson syndrome (Báez-Ferrer 2019), toxic epidermal necrolysis, urticaria (Cheema 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Insulin autoimmune syndrome (Rajpal 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia (Cave 2008), colitis (including ulcerative colitis or lymphocytic colitis), diarrhea, duodenal ulcer (Ebi 2018), gastric ulcer, pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired blood coagulation disorder (hemophilia A), agranulocytosis, aplastic anemia (Uz 2010), pancytopenia (Matthews 2009), thrombotic thrombocytopenic purpura (Zakarijia 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Monteiro 2011), hepatitis (noninfectious) (Pisapia 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Cheema 2011), nonimmune anaphylaxis, serum sickness (Phillips 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Inagaki 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, hallucination (Osuagwu 2016), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Coulter 2012), arthritis (Garg 2000), myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, eosinophilic pneumonitis (Inagaki 2020), interstitial pneumonitis (Tomoda 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Cheema 2011)</p></div>
<div class="block coi drugH1Div" id="F153611"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to clopidogrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Significant liver impairment or cholestatic jaundice; concomitant use of repaglinide.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F153595"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C19 poor metabolizers: <b></b>Routine platelet function testing or genetic testing for CYP2C19 polymorphisms is not recommended (ACC/AHA [Levine 2016]; Scott 2013; Sibbing 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. If antiplatelet agents are discontinued, they should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk. Aspirin should generally <i>not</i> be discontinued. Dual antiplatelet therapy (DAPT) should generally <i>not </i>be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients undergoing cardiac surgery (eg, coronary artery bypass graft surgery), discontinue clopidogrel at least 24 hours and up to 5 days before surgery in consultation with a cardiologist, interventional cardiologist, and cardiac surgeon (ACC/AHA [Grines 2007]; ACC/AHA [Lawton 2022]). In patients undergoing noncardiac surgery, the risks and benefits of clopidogrel should be evaluated between the surgeon and the cardiology team. Elective noncardiac surgery should not be performed in patients in whom DAPT will need to be discontinued perioperatively within 30 days following bare metal stent placement or within 3 months of drug-eluting stent placement. In patients undergoing urgent noncardiac surgery during the first 4 to 6 weeks after BMS or DES placement, DAPT may be continued. In patients undergoing noncardiac surgery that requires discontinuation of clopidogrel, hold for 5 days preoperatively, continue aspirin and re-start clopidogrel as soon as possible (eg, ≤24 hours) after surgery based on bleeding and thrombotic risks (ACC/AHA [Fleisher 2014]; ACC/AHA [Lawton 2022]; ACC/AHA [Levine 2016]; ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: For patients who undergo percutaneous coronary intervention with stenting, premature interruption of therapy may result in increased risk of myocardial infarction, stent thrombosis, stroke, or death. If therapy must be held temporarily (eg, bleeding, surgery), restart as soon as possible. Duration of therapy is determined by the type of stent placed (bare metal or drug eluting), whether an acute coronary syndrome event was ongoing at the time of placement, as well as risks for bleeding and thrombosis (ACC/AHA [Lawton 2022]).</p></div>
<div class="block foc drugH1Div" id="F153606"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plavix: 75 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F153591"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F153613"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Clopidogrel Bisulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $6.57 - $6.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $15.94 - $27.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Plavix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $9.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866402"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plavix: 75 mg, 300 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg, 300 mg</p></div>
<div class="block exp drugH1Div" id="F10806355"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>5 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 5 mg/mL oral suspension may be made using tablets. Crush four 75 mg tablets and reduce to a fine powder. Add a small amount of a 1:1 mixture of Ora-Sweet and Ora-Plus and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well". Stable 60 days at room temperature or under refrigeration.</p>
<div class="reference">Skillman KL, Caruthers RL, and Johnson CE, "Stability of an Extemporaneously Prepared Clopidogrel Oral Suspension," <i>Am J Health Syst Pharm</i>, 2010, 67(7):559-61.<span class="pubmed-id">20237383</span></div>
</div>
<div class="block admp drugH1Div" id="F52612443"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>NG tube: </i>Consider use of extemporaneously compounded oral suspension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20237383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20237383'])">Ref</a></span>); alternatively, based on experience in adult patients, may crush tablet(s), mix with 10 mL of water, draw dose volume into a syringe for NG administration, and administer; after administration flush syringe and NG tube with an additional 20 mL of water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496900'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F9480379"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals. May administer through an NG tube by crushing tablet(s), mixing with 10 mL of water, drawing into a syringe then flushing down the NG tube; flush syringe and NG tube with an additional 20 mL of water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496900'])">Ref</a></span>). Compounding an extemporaneously prepared oral suspension has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20237383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20237383'])">Ref</a></span>). Additionally, tablets may be crushed and mixed with sterile water or with Ora-Sweet and Ora-Plus for use in desensitization protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18225971','lexi-content-ref-18021870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18225971','lexi-content-ref-18021870'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F153622"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F11566548"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F020839s072lbl.pdf%23page%3D24&amp;token=kRaK8wNgoMnm9WSwbAwtps8Z2PPGF1fP9LhZu%2B1uLvKH%2BhBJCaSZBrfzcAvVZPP%2B1TEkrequS0jYxtyMhEv6XcCTdlvIrd0wJ6Dllo5%2BFylBpaFzvDb4bi5OyrknRJdj&amp;TOPIC_ID=12984" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020839s072lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53566166"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Reduction of atherothrombotic events (myocardial infarction [MI], stroke, and vascular deaths) in patients with recent MI, stroke, or established peripheral arterial disease (FDA approved in adults); reduction of atherothrombotic events in patients with non-ST-segment elevation acute coronary syndrome (unstable angina and non-ST-elevation MI) managed medically and with coronary revascularization (FDA approved in adults); reduction of death rate and atherothrombotic events in patients with acute ST-elevation MI (STEMI) managed medically (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F153666"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Plavix may be confused with Elavil, Paxil, Pradax (Canada), Pradaxa</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F153651"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2B6 (weak), CYP2C8 (moderate)</p></div>
<div class="block dri drugH1Div" id="F153600"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Alpelisib.  Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May diminish the antiplatelet effect of Clopidogrel. Atazanavir may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Coadministration of clopidogrel and atazanavir is not recommended and alternative should be sought if possible. If combined, monitor closely for evidence of diminished antiplatelet response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: BCRP/ABCG2 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with BCRP inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inhibitors (Weak) may increase the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: May diminish the therapeutic effect of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cangrelor: May diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopidogrel, Cangrelor is expected to decrease binding of Clopidogrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. Management: Avoid administration of clopidogrel until cangrelor infusion is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: BCRP/ABCG2 Inhibitors may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Consider alternatives to this combination when possible, as HIV treatment guidelines recommend that this combination not be coadministered. If coadministered, monitor closely for evidence of diminished antiplatelet response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clopidogrel. Management: Consider alternatives to this combination when possible. If combined, monitor for increased clopidogrel effects and toxicities (eg, bleeding) if clopidogrel is combined with a strong CYP2C19 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Consider alternatives to this combination whenever possible. If such a combination must be used, monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danshen: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Danshen may decrease the serum concentration of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Daprodustat.  Management: Reduce the daprodustat starting dose by half if combined with moderate CYP2C8 inhibitors, unless the dose is 1 mg, then no dose adjustment is required. Monitor hemoglobin and adjust daprodustat dose when starting or stopping moderate CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dasabuvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desloratadine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Desloratadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Diamorphine may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Enzalutamide. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May diminish the antiplatelet effect of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole: May diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Consider alternatives to clopidogrel in patients treated with etravirine. If combined, monitor for reduced clopidogrel effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Advise patients receiving clopidogrel to minimize consumption of grapefruit and grapefruit juice.  Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May diminish the antiplatelet effect of Clopidogrel. Nirmatrelvir and Ritonavir may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Avoid coadministration of clopidogrel and nirmatrelvir/ritonavir when possible. Consider using alternative COVID-19 therapy or an alternative antiplatelet such as prasugrel if clinically appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the concentrations of the dasabuvir component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP2C8 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP2C8 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pantoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel. Other acid-lowering therapies do not appear to share this interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: Clopidogrel may increase the serum concentration of Repaglinide.  Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg. This is contraindicated in some non-US labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May diminish the antiplatelet effect of Clopidogrel. Ritonavir may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Avoid coadministration of clopidogrel and ritonavir-boosted protease inhibitors. If coadministration cannot be avoided, monitor closely for evidence of diminished antiplatelet response to clopidogrel with use of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: BCRP/ABCG2 Inhibitors may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag.  Management: Reduce the selexipag dose to once daily when combined with moderate CYP2C8 inhibitors. Revert back to twice daily selexipag dosing upon stopping the moderate CYP2C8 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sibutramine: CYP2B6 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Sibutramine. CYP2B6 Inhibitors (Weak) may increase the serum concentration of Sibutramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Zirconium Cyclosilicate: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Separate the administration of sodium zirconium cyclosilicate and clopidogrel by at least 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treprostinil: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Treprostinil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: BCRP/ABCG2 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: May diminish the therapeutic effect of Clopidogrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Clopidogrel may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F153623"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. Management: Avoid or minimize the consumption of grapefruit or grapefruit juice (Holmberg 2013).</p></div>
<div class="block dic drugH1Div" id="F153614"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid or minimize the consumption of grapefruit juice (Holmberg 2013).</p></div>
<div class="block pri drugH1Div" id="F3343717"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to use during pregnancy is limited (Bauer 2012; De Santis 2011; Myers 2011). Based on available data, an increased risk of major birth defects, miscarriage, or adverse fetal outcomes has not been associated with maternal use of clopidogrel. According to the manufacturer, use should not be withheld if needed for emergent treatment of stroke or myocardial infarction during pregnancy. Discontinue use 5 to 7 days prior to labor, delivery, or neuraxial blockade if possible due to increased risk of maternal bleeding and hemorrhage.</p>
<p style="text-indent:0em;margin-top:2em;">Available guidelines recommend using clopidogrel only when strictly needed and for the shortest duration possible until additional fetal safety data are available (ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53566168"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of bleeding; hemoglobin and hematocrit periodically. Monitor mean inhibition of platelet aggregation: Goal of 30% to 50% inhibition (similar to adults receiving 75 mg/day). For unstable angina/non-ST-elevation myocardial infarction in adults, platelet function testing has been used to determine platelet inhibitory response if results of testing may alter management (Wright 2011).</p></div>
<div class="block pha drugH1Div" id="F153594"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Clopidogrel requires <i>in vivo</i> biotransformation to an active thiol metabolite. The active metabolite irreversibly blocks the P2Y<sub>12</sub> component of ADP receptors on the platelet surface, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7 to 10 days).</p></div>
<div class="block phk drugH1Div" id="F153610"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Inhibition of platelet aggregation (IPA): Dose-dependent:</p>
<p style="text-indent:-2em;margin-left:4em;">300 to 600 mg loading dose: Detected within 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">50 to 100 mg/day: Detected by the second day of treatment</p>
<p style="text-indent:-2em;margin-left:2em;">Peak effect: Time to maximal IPA: Dose-dependent: <b>Note:</b> Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry:</p>
<p style="text-indent:-2em;margin-left:4em;">300 to 600 mg loading dose:</p>
<p style="text-indent:-2em;margin-left:6em;">ADP 5 micromole/L: 20% to 30% IPA at 6 hours post administration (Montelescot 2006)</p>
<p style="text-indent:-2em;margin-left:6em;">ADP 20 micromole/L: 30% to 37% IPA at 6 hours post administration (Montelescot 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">50 to 100 mg/day: ADP 5 micromole/L: 50% to 60% IPA at 5 to 7 days (Herbert 1993)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Platelet aggregation and bleeding time gradually return to baseline after ~5 days after discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Parent drug: 98%; Inactive metabolite (carboxylic acid derivative): 94%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via esterase-mediated hydrolysis to a carboxylic acid derivative (inactive) and via CYP450-mediated (CYP2C19 primarily) oxidation to a thiol metabolite (active)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: ~6 hours; Thiol derivative (active metabolite): ~30 minutes; carboxylic acid derivative (inactive; main circulating metabolite): ~8 hours; <b>Note:</b> A clopidogrel radiolabeled study has shown that covalent binding to platelets accounts for 2% of radiolabel and has a half-life of 11 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~0.75 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Following administration of a single <sup>14</sup>C-labeled clopidogrel oral dose; radioactivity measured over 5 days: Urine (50%); feces (46%)</p></div>
<div class="block phksp drugH1Div" id="F51220853"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: After repeated doses of clopidogrel 75 mg/day, patients with severe (CrCl 5 to 15 mL/minute) and moderate (CrCl 30 to 60 mL/minute) renal impairment showed low (25%) inhibition of ADP-induced platelet aggregation.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Less inhibition of ADP-induced platelet aggregation was observed in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F153615"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Anogrel | Antiplex | Clopacin | Clopidocor | Clopigen | Clopimet | Deplatt | Emivix | Livigrel | Novogrel | Oneclapz | Pedovex | Plavix | Thinrin | Zygrel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Antiplaq | Ariclopin | Clodian | Clodinarel | Clodrel | Clopidogrel northia | Clopidogrel puntanos | Clopidogrel Richet | Clopidogrel Rospaw | Clopidogrel savant pharm | Clopidogrel teva | Clopilep | Iscover | Micro cape | Monrex | Nabratin | Nadenel | Nefazan | Plaquetriol | Plataca | Plavix | Pleyar | Triurol | Troken | Ximara</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aclop | Clogagren | Clogombix | Clogrelhexal | Clopidogrel | Clopidogrel +pharm | Clopidogrel 1a pharma | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel aliud | Clopidogrel G.L. | Clopidogrel Genericon | Clopidogrel krka | Clopidogrel medico uno | Clopidogrel Mylan | Clopidogrel ranbaxy | Clopidogrel Ratiopharm | Clopidogrel Ratiopharm gmbh | Clopidogrel sandoz | Clopidogrel Stada | Cloroden | Grelidohex | Grepid | Plavix | Zopya | Zyllt</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo clopidogrel | Blooms the chemist clopidogrel | Chemmart Clopidogrel | Clopidogrel | Clopidogrel Actavis | Clopidogrel an | Clopidogrel drla | Clopidogrel ga | Clopidogrel lupin | Clopidogrel PS | Clopidogrel Rbx | Clopidogrel winthrop | Clovix | Iscover | Piax | Plavicor | Plavix | Plidogrel | Stada clopidogrel | Terry White Chemists Clopidogrel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anclog | Anlet | Anplat | Athorel | Carceva | Cardogrel | Clavix | Clocard | Clognil | Clont | Clopid | Clorel | Dclot | Dorel | Lirel | Livocard | Lopirel | Noclog | Odrel | Pladex | Plagrin | Platrel | Plavix | Preclot | Replet | SB clopido</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel ab | Clopidogrel apotex | Clopidogrel doc | Clopidogrel EG | Clopidogrel Krka d.d. | Clopidogrel Mylan | Clopidogrel Ratiopharm | Clopidogrel Stada | Clopidogrel taw pharma | Clopidogrel Teva | Clopidogrel Zentiva | Clopidomed | Clopinovo | Plavix | Zopya | Zyllt</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Antiplatt | Arteropirine | Cardogrel | Clopact | Clopi denk | Clopid | Instaclop | Nugrel | Plavix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clopidocon | Clopidogrel | Clopidogrel ecopharm | Clopidogrel gsk | Clopidogrel medico uno | Clopidogrel Ratiopharm | Clopidogrel stada | Clopidogrel Teva | Clopigamma | Egitromb | Glopenel | Kaldera | Plaquex | Platel | Plavix | Plavocorin | Trombex | Vatoud | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Agreg | Aterogrel | Bissulfato de clopidogrel | Clopido gran | Clopidogran | Clopidogrel | Clopidror | Clopin | Clopiplax | Clopivix | Cuore | Iscover | Lopigrel | Paqueta | Plagrel | Plaq | Plaquetel | Plaquevix | Plavix | Vasolen | Vixgrel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clogrel | Clopidogrel actavis | Clopidogrel Axapharm | Clopidogrel Mepha | Clopidogrel sandoz | Clopidogrel sodip | Clopidogrel spirig | Clopidogrel streuli | Clopidogrel Teva | Clopidogrel winthrop | Clopidogrel Zentiva | Clopidrax | Iscover | Plavix</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Agreter | Antiplatt | Arteropirine | Ceruvin | Clopact | Clopi denk | Clopid | Clopidogrel Zentiva | Clopivas | Copigrel | Instaclop | Nugrel | Redus | Subrigel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Agreplat | Artevil | Clentel | Clopidogrel | Clopivitae | Clotrombix | Fluyet | Iskimil | Piclokare | Plavix | Ravalgen | Sildecross</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">En cun | Plavix | Tai jia | Talcom</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Algilis | Atelit | Ateplax | Cardiogrel | Clentel | Clopax | Clopidogrel | Clopivas | Flusan | Hogel | Iscover | Nodit | Platemax | Plavix | Terotrom | Tiplac | Tisten | Trimedat | Tromboxtyl | Vicafidt</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Zopya | Zyllt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel al | Clopidogrel apotex | Clopidogrel gsk | Clopidogrel Mylan | Clopidogrel Orion | Clopidogrel pharmiks | Clopidogrel Stada | Clopidogrel Teva | Clopigamma | Clopimyl | Clopithan | Cloroden | Egitromb | Lopigalel | Nofardom | Platel | Plavix | Plavocorin | Tessyron | Trogran | Trombex | Tuxedon | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carder | Clopacin | Clopidocard | Clopidocor | Clopidogrel | Clopidogrel AAA | Clopidogrel Acino | Clopidogrel Actavis | Clopidogrel al | Clopidogrel amneal | Clopidogrel aristo | Clopidogrel Arrow | Clopidogrel Aurobindo | Clopidogrel axcount | Clopidogrel Basics | Clopidogrel Biomo | Clopidogrel CT | Clopidogrel Denk | Clopidogrel Dexcel | Clopidogrel Dr. Reddys | Clopidogrel Dura | Clopidogrel genevida | Clopidogrel gib | Clopidogrel glenmark | Clopidogrel HCS | Clopidogrel hec pharm | Clopidogrel Hennig | Clopidogrel heumann | Clopidogrel Hexal | Clopidogrel Hormosan | Clopidogrel hydrochlorid 1A pharma | Clopidogrel krka | Clopidogrel macleods | Clopidogrel Ratiopharm | Clopidogrel Sandoz | Clopidogrel Stada | Clopidogrel TAD | Clopidogrel teva pharma | Clopidogrel winthrop | Clopidogrel Zentiva | Clopidolut | Clopigamma | Clopipuren | Grepid | Iscover | Narutis | Plavix | Rokulan | Subarcan | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">0 Tromb | Agyl | Aplagrel | Atelit | Bisfar | Clentel | Clocard | Clodopaq | Clonidox | Clopibrit | Clopidogrel | Clopidogrel MF | Clopidogrel mk | Clopidogrel sandoz | Clopifel | Clopifran | Clopisev | Cloprez | Clovart mm | Coragrec | Corpirox | Darlax | Degregan | Euroclopid | Expansia | Iberogrel | Liquoflex | Lisplag | Nabratin | Noplak | Nugrel | Nuvax | Pidrox | Plavix | Proplavigrel | Vascultren | Venoparin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acrogrel | Agrelax | Antigrel | Atelit | Ateplax | Clentel | Clopacin | Clopido gran | Clopidogrel | Clopikana | Clopilet | Clopistal-75 | Coenxiol | Eurogrel | Expansia | Grelix | Plagril | Plavix | Troken</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel krka | Clopidogrel portfarma | Clopidogrel Ratiopharm | Clopidogrel sanoswiss | Clopidogrel teva | Clopigamma | Clopimef | Glopenel | Lofradyk | Nofardom | Plavix | Plavocorin | Trombex | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Angosmooth | Blotagril | Borgavix | Clatex | Clopex | Clopexagrel | Contrastroke | Fibrogrel | Idiavix | Myogrel | Orgistrok | Platenor | Plavedamol | Plavicard | Plavictonal | Plavix | Sigmagrel | Stroka | Thrombo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Agrelan | Clopidogrel | Clopidogrel Actavis | Clopidogrel almus | Clopidogrel Alter | Clopidogrel amneal | Clopidogrel Aphar | Clopidogrel apotex | Clopidogrel Arrow | Clopidogrel Bexala | Clopidogrel Cinfa | Clopidogrel Combix | Clopidogrel curaxys | Clopidogrel Edigen | Clopidogrel HCS | Clopidogrel Kern | Clopidogrel krka | Clopidogrel Mabo | Clopidogrel Mylan | Clopidogrel mylan pharmaceuticals | Clopidogrel normon | Clopidogrel Pensa | Clopidogrel pharma combix | Clopidogrel Pharmacia | Clopidogrel Qualigen | Clopidogrel ranbaxy | Clopidogrel Ratiopharm | Clopidogrel sandoz | Clopidogrel Tarbis | Clopidogrel tecnigen | Clopidogrel teva | Clopidogrel ur | Clopidogrel viatris | Clopidogrel Vir | Clopidogrel Zentiva | Grepid | Iscover | Maboclop | Plavix | Vatoud | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Clopi denk | Clopidogrel | Clopidogrel bisulphate | Clopivid | Pedovex | Platil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel accord | Clopidogrel Actavis | Clopidogrel HCS | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel Orion | Clopidogrel Refta | Clopidogrel Stada | Clopidogrel taw pharma | Clopidogrel Teva | Clopidogrel Zentiva | Clopidrion | Cloriocard | Grepid | Plavix | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel abbott | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel Almus | Clopidogrel Alter | Clopidogrel Arrow generiques | Clopidogrel Biogaran | Clopidogrel Bouchara-Recordati | Clopidogrel Cristers | Clopidogrel EG | Clopidogrel Evolugen | Clopidogrel HCS | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel phr | Clopidogrel Qualimed | Clopidogrel Ratiopharm gmbh | Clopidogrel RPG | Clopidogrel sandoz | Clopidogrel viatris | Clopidogrel Wyeth | Clopidogrel Zydus | Plavix | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel almus | Clopidogrel teva | Grepid | Plavix | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bidogrel | Blodegrel | Carder | Clocardio | Clodel | Clopadel | Clopidogrel | Clopidogrel apotex | Clopidogrel Mylan | Clopidogrel Zentiva | Clopidogrel/genepharm | Clopidogrel/velka | Clopidosyn | Cloplate | Cloriocard | Cloroden | Clovelen | Dapixol | Darxa | Dasogrel s | Demogrel | Denovex | Diclop | Espelio | Globel | Glopenel | Greligen | Grepid | Heart Free | Iscodil | Iscover | Isroen | Larvin | Niaclop | Novigrel | Optigrel | Placard | Plasiver | Platel | Plavidosa | Plavix | Plavogrel | Sanvix | Tansix | Throimper | Unplaque | Zopya | Zylagren | Zyllt | Zystol</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Plaxin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Anclog | Antiplatt | Apo clopidogrel | Clavix | Clopidogrel | Clopidogrel Actavis | Clopidogrel sandoz | Clopistad | Clopivas | Clopivid | Clopra | Copalex | Gridokline | Lopirel | Norplat | Plavix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Angiclod | Clopidogrel krka | Farcet | Gardin | Iscover | Klopidex | Klopidogrel Genera | Klopidogrel PharmaS | Kogrel | Pigrel | Plavix | Zyllt</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Agrelex | Atrombin | Clopidep | Clopidogrel Actavis | Clopidogrel gsk | Clopidogrel Hexal | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel Q Pharma | Clopidogrel Ratiopharm | Clopidogrel teva | Clopigamma | Clopithan | Defrozyp | Egitromb | Kardogrel | Kerberan | Lofradyk | Nofardom | Plagrel | Plavix | Trogran | Trombex | Tuxedon | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Artepid | Clidorel | Clogin | Clopid | Clopidogrel | Clopidogrel Fahrenheit | Clopidogrel ikapharmindo | Clopisan | Clotix | Clovillet | Copidrel | Cpg | Febogrel | Insigrel | Pidovix | Placta | Pladel | Pladogrel | Platec | Plavix | Plavos | Rinclo | Simclovix | Therodel | Trombikaf | Vaclo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clodel | Clopidogrel | Clopidogrel actavis | Clopidogrel clonmel | Clopidogrel gerard | Clopidogrel krka | Clopidogrel niche | Clopidogrel Teva | Grepid | Plavix | Zopya | Zyllt</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Clood | Plavix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aclotil | Adplatt | Antiban | Anticog | Antiplar | Antiplatt | Anziolet | Aptogrel | Blothin | C gril | Caplor | Cargrel | Ceruvin | Cidogrel | Clavix | Clearclot | Clobest | Clodrel | Cloflow | Clofre | Clolyse | Clopace | Clopact | Clopcare | Clope | Clopicard | Clopicare | Clopicheck | Clopicure | Clopid | Clopiflo | Clopigrel | Clopihenz | Clopijoy | Clopikind | Clopiklot | Clopilar | Clopilet | Clopione | Clopirad | Clopitab | Clopivas | Clopiwok | Cloplat | Clopod | Cloprez | Clotsafe | Cloyd | Cpg | Deplatt | G-Life | Grel | Ibclop | Instaclop | Klotfree | Klov | Noklot | Noplaq | Nugrel | Nurgel | Orawis | Pidlet | Plagerine | Plagril | Plagril gold | Platfree | Platloc | Plavix | Plaxia | Preva | Stromix | Superclop | Themigrel | Thinrin | Torpido | Torplatt | Vixplat | Zeter | Zogrell</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Aswdogrel | Flowvix | Plavedain | Plavikin | Plavineer</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Averelix | Carder | Clopidogrel Actavis | Clopidogrel almus | Clopidogrel Alter | Clopidogrel Aurobindo | Clopidogrel doc | Clopidogrel dr reddy's | Clopidogrel EG | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel mylan generics | Clopidogrel Pensa | Clopidogrel Ratiopharm | Clopidogrel san | Clopidogrel spl | Clopidogrel tecnigen | Clopidogrel tev | Clopidogrel teva | Clopidogrel Zentiva | Clopigamma | Clopinovo | Grepid | Iscover | Plavix | Revlis | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aggrix | Antiplex | Clopidocor | Cloplav | Clovex | Instaclop | Pedovex | Platil | Plavix | Thrombonil | Trombex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel nipro | Plavix</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Antiplatt | Cadigrel | Caplor | Cardogrel | Ceruvin | Cloflow | Clopacin | Clopact | Clopi | Clopi denk | Clopicip | Clopid | Clopidowel | Clopikind | Clopilet | Clopress | Cloprez | Cosgrel | Deplatt | Explat | Flamogrel | Frelet | Instaclop | Lowplat | Noclog | Noclot | Norplat | Nugrel | Plasep | Platfree | Plavix | Plaxylet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anavix | Antipla | Aprogen clopidogrel | Arahan | Atcrel | Aukodorel | Bigtogrel | Brvix | Celavix | Cerenade | Chrorel | Citgrel | Claudel | Clavixin | Clidel | Clinvix | Clivix | Clo v | Cloart | Clobons | Clochance | Clocover | Clocure | Clod | Clodid | Clodorel | Clodown | Clodril | Clogrel | Clomedi | Clopect | Clopi | Clopi lt | Clopick | Clopid | Clopidil | Clopido | Clopidogrel | Clopidogrel daewon | Clopigel | Clopigen | Clopil | Clopin | Clopina | Clopio | Clopirel | Clopiren | Clorin | Clostar | Clotec | Clovein | Clovid | Clovix | Clovons | Clowin | Cloze | Clozex | Clpido | Clpidoem | Clpigrel | Clvix | Cravix | Crevix | Curovix | Dong a pharm clopidogrel bisulfate | Dongsung clopidogrel | Erabigs | Flatogrix | Glogrel | Glopidogrel | Grory | Hanvix | Hivix | Huniz clopidogrel bisulfate | Hurofix | Hyundai clopidogrel | I clo | I-clo | Ilyangbio clopidogrel sulfate | Inhipla | Inhiplat | Inist clopidogrel | Inno.n clopidogrel | Jgrel | K Grel | K pla | Kerapix | Kovix | Krivix | Kuhnil clopidogrel | Kyongbo clopidogrel | Limpizen | Lopirel | Maxgrel | Medicgrel | Myungmoon clopidogrel | Neovix | New clopine | Newpido | Newvix | Pabiclen | Pharmbio korea clopidogrel bisulfate | Pharviclen | Pidogel | Pidogrin | Pidogul | Pidorel | Pidovix | Pilgrel | Plabitor | Plagrel | Plakim | Plamed | Planexine | Platless | Plavel | Plavitor | Plavix | Plavixen | Plvix | Prabigsen | Pravic | Pravix | Pregrel | Preto | Provic | Provict | Provix | Q.O.L | Qurovex | Reyon clopidogrel | Rp clopia | Sama clopidogrel | Sd clo | Telogrel | Trombix | Tromvix | Ubix | Vasobics | Woorivix | Young il clopidogrel | Yugrel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Antiplex | Clopacin | Clopivid | Pedovex | Plavix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aggrix | Antiplex | Apo clopidogrel | Ceruvin | Clodor | Clopacin | Clopexagrel | Clopidocor | Clopidogrel Arrow | Clopimed | Clotrix | Clovex | Grepid | Mogrel | Nefazan | Normigore | Pedovex | Pidogrel | Plagin | Platil | Plavinor 75 | Plavix | Redus | Thrombo | Troken | Xydrel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel Orion | Clopidogrel portfarma | Clopidogrel Ratiopharm | Clopidogrel sandoz | Clopidogrel sanoswiss | Clopidogrel teva | Clopidogrel torrent | Clopidrogel Sandoz | Clopigamma | Clopimef | Egitromb | Grepid | Lofradyk | Nofardom | Platel | Plavix | Plavocorin | Trombex | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel EG | Clopidogrel Mylan | Clopidogrel Ratiopharm | Clopidogrel sandoz | Plavix | Zopya | Zyllt</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel krka | Clopidogrel portfarma | Clopidogrel Ratiopharm | Clopidogrel sanoswiss | Clopidogrel teva | Clopigamma | Clopimef | Egitromb | Glopenel | Grepid | Nofardom | Platel | Plavix | Plavocorin | Trombex | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Agrel | Agreter | Cardiogrel | Ceruvin | Clopicard | Digrel | Inilase | Pedovex | Plarel | Plavix</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acovix | Adiverbos | Aggreles | Agreless | Arcost | Biosahani | Cidorix | Clodogrex | Clopidogrel | Degregan | Deviplat | Dogrenap | Eurus | Fabiplac | Flucogrel | Grenpharma | Hexyr | Iscover | Klotfree | Krezeva | Laquex | Legrelex | Nabratin | Olfovel | Plavix | Retaq | Vicafidt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Antiplatt | Apo clopidogrel | Cardivix | Ceruvin | Clavix | Clopi | Clopidogrel | Clopidogrel stada | Clopivas | Clopivid | Deplatt | Gridokline | Kogrel | Placta | Plagril | Plavix | Troken | Vitraq</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Antiplar | Bluevix | Cegrel | Clodorel | Clopi denk | Clopidogrel | Clopikind | Clopilad | Dogrel | Ideal eagles clopidogrel | Meks clopidogrel | Myogrel | Nigrel | Novogrel | Odrel | Oneclapz | Plavido | Previx | Rumagrel | Tricare clopidogrel | Zelix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel apotex | Clopidogrel Delphi | Clopidogrel krka | Clopidogrel xiromed | Clopidogrel Zentiva | Grepid | Iscover | Plavix | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Clopidogrel accord | Clopidogrel Actavis | Clopidogrel amneal | Clopidogrel aristo | Clopidogrel krka | Clopidogrel taw pharma | Clopidogrel Zentiva | Grepid | Plavix</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo clopidogrel | Arrow Clopidogrel | Clopidogrel multichem | Plavix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Atelit | Ateplax | Aterogrel | Clopidogrel | Clopifar | Clopilet | Clopiquel | Clopirite | Clopistal 75 | Clopivas | Clopivitae | Clovexil | Eurogrel | Nabratin | Novogrel | Panagrel | Pidogrel-N | Plagerine | Plagrel | Plavix | Preva | Triosal | Vasocor | Vidogrel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actaclo | Angiogrel | Anplat | Artheogrel | Atheros | Avancur | Cardogrel | Carlopid | Cigrel | Clapidz | Class | Clomep | Clomex | Clopate | Clopend | Clophil | Clopida | Clopido | Clopido M | Clopidoflo | Clopidogen | Clopidogrel | Clopidogrel winthrop | Clopidowel | Clopidra | Clopidrol | Clopifar | Clopimed | Clopimet | Clopinova | Clopiric | Clopistad | Clopivin | Clopiwin | Clopix | Cloplat | Cloprez | Clotfixmed | Clotigen | Clotiz | Clovas | Clovax | Clovix | Corplet | Declot | Deplatt | Doploc | Dorell | Flamdovix | Hemaflow | Hivix | Klopi | Lifegrel | Loclog | Medogrel | Navorel | Neoclopid | Noklot | Norplat | Pharex clopidogrel | Pharmagrel | Platelex | Platexan | Platz | Plavihex | Plavix | Plogrel | Proflow | Saphlopid | Syclopid | Thromvix | Timibest | Timiflo | Tridogrel | Trombix | Vexagril | Vivelon | Xerevo | Zandropil | Zeroclot</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abiclot | Actiplat | Agranil | Ateplex | Clogpid | Clogrel | Clopeg | Clopido | Clopidob | Clopidro | Clopisel | Clopivax | Clopivel | Clorel | Clotinil | Clotles | Clotnil | Cloxidil | Cocard | Codril | Deplat | Deplug | Disclot | Dogrel | Enclot | Everclo | Explat | Extrac | Fleet | Isteblix | Janplate | Klolet | Kloprin | Kumplat | Loclog | Lowplat | Maxises | Nilclot | Noclot | Noclot ld | Norplat | Ogrel | Patla | Plafix | Plagril | Platagg-1 | Platex | Platlo | Platrid | Plaveryl | Plavix | Previx | Progrel | Rayplat | Revive | Revive pro | Riplan | Seaclop | Simgrel | Sydoclop | Thrombonil | Wascorel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Agregex | Areplex | Carder | Clogrel | Clopidix | Clopidogrel Actavis | Clopidogrel apotex | Clopidogrel Arrow | Clopidogrel gsk | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel ranbaxy | Clopidogrel teva | Clopidogrelum 123ratio | Clopigamma | Clopinovo | Egitromb | Grepid | Lopigalel | Miflexin | Nivenol | Pegorel | Plavix | Plavocorin | Trogran | Trombex | Tuxedon | Vixam | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel | Plavix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aeme | Balplak | Cereflow | Clopid | Clopid Anairam | Clopid Hemopass | Clopid Krival | Clopid Vida | Clopidogrel | Clopidogrel Actavis | Clopidogrel Adapes | Clopidogrel alirom | Clopidogrel Alter | Clopidogrel aurovitas | Clopidogrel Azevedos | Clopidogrel Blocel | Clopidogrel bluepharma | Clopidogrel ciclum | Clopidogrel Farmoz | Clopidogrel Generis | Clopidogrel generis phar | Clopidogrel germed | Clopidogrel gp | Clopidogrel Kaissan | Clopidogrel krka | Clopidogrel labesfal | Clopidogrel Merck | Clopidogrel Mylan | Clopidogrel pensa | Clopidogrel Pentafarma | Clopidogrel Refta | Clopidogrel resmag | Clopidogrel TAD | Clopidogrel teva | Clopidogrel teva pharma | Clopidogrel trafar | Clopidogrel wynn | Clopidogrel Zentiva | Iscover | Keriten | Krossiler | Plavix | Pravidel | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alartrom | Angor | Clentel | Clonidox | Clopidogrel biosano | Clopidogrel dasanti | Clopidogrel dutriec | Clopidogrel empa | Clopidogrel genfar | Clopidogrel imedic | Clopidogrel la sante | Clopidogrel prosalud | Clopidogrel sandoz | Dogrek | Eurogrel | Inhiplaq | Lopidrox | Mival | Nefazan | Notrom | Pidogrel | Plastec | Plavix | Pravidel | Ravalgen | Sutrim | Troken</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Antiplex | Cupido | Deplatt | Grepid | Normigore | Pedovex | Pido | Platil | Plavix | Zygrel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel actavis | Clopidogrel Aurobindo | Clopidogrel bgr | Clopidogrel dr reddy's | Clopidogrel Eipico | Clopidogrel polipharma | Clopidogrel terapia | Clopidogrel teva | Clopigamma | Cloroden | Defrozyp | Deplatt | Egitromb | Lofradyk | Tessyron | Trogran | Trombex | Tuxedon | Vatoud | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agregal | Cardogrel | Cardutol | Clopidex | Clopidogrel | Clopidogrel fpo | Clopidogrel richter | Clopidogrel tad | Clopidogrel teva | Clopidogrel velpharm | Clopidogrel-leksvm | Clopigrant | Clopilet | Deplatt | Detromb | Detrombe | Egitromb | Fagot | Klapitaks | Lirta | Listab 75 | Lopirel | Plagril | Plavix | Plogrel | Targetek | Troken | Tromborel | Zilt | Zyllt</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo clopidogrel | Cardlet | Clogrel | Clopacin | Clopex | Cupido | Paleta | Pedovex | Peevo | Plavix | Ravixa | Vidapart</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clopidogrel accord | Clopidogrel Actavis | Clopidogrel amneal | Clopidogrel aristo | Clopidogrel Aurobindo | Clopidogrel krka | Clopidogrel Mylan | Clopidogrel Orion | Clopidogrel Pensa | Clopidogrel Ratiopharm | Clopidogrel Stada | Clopidogrel stada | Clopidogrel taw pharma | Clopidogrel Teva Pharma B.V. | Clopidogrel winthrop | Clopidogrel Zentiva | Cloriocard | Grepid | Klopidogrel Arrow | Plavix | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo clopidogrel | Clopidogrel Sandoz | Clopidogrel stada | Clopidogrel winthrop | Deplatt | Placta | Plagril | Platless | Plavix | Thinoclo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Agrelex | Clopez | Clopidogrel actavis | Clopigamma | Klopidogrel Actavis | Klopidogrel Mylan | Klopidogrel Teva | Plavix | Pontius | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Agrelex | Carder | Cloper | Clopidogrel accord | Clopidogrel actavis | Clopidogrel krka | Clopidogrel Medico | Clopidogrel Mylan | Clopidogrel Orion | Clopidogrel Stada | Clopidogrel TAD | Clopidogrel teva | Clopigamma | Clopithan | Egitromb | Grepid | Nofardom | Platel | Plavix | Plavocorin | Trogran | Trombex | Tuxedon | Zopya | Zylagren | Zyllt</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apolets | Ceruvin | Clopidogrel sandoz | Oklot | Platogrix | Plavix</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Agregex | Clopix | Cloven | Copigrel | Pedovex | Pidogrel | Plagrel | Plavix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">As Clodip | Atervix | Baclan | Clogan | Cloperol | Clopitro | Clopra | Corrente | Diloxol | Diporel | Karum | Klopis | Opirel | Pingel | Planor | Plavega | Plavidol | Plavix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo clopidogrel | Canafi | Clofix | Cloflow | Clofree | Clogrel | Clopid | Clopidogrel | Clopistad | Clotinil | Clovvix | Cotol | Noklot | Platon | Plavix | Thrombifree</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Agrel | Aterocard | Atrogrel | Cardogrel | Clodia | Clopidexcel | Clopidogrel | Clopidogrel apo | Clopidogrel teva | Clopigrel | Clopilet | Clopix | Flamogrel | Lodigrel | Lopigrol | Lopirel | Medogrel | Noclot | Nugrel | Oneklapz | Pingel | Pingel neo | Plagril | Platogrel | Platogril | Plavix | Plazep | Reodar | Reomax | Trombonet</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cadigrel | Caplor | Clopi | Clopi denk | Clopivas | Clopraz | Instaclop | Noklot | Nugrel | Platfree</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Clopigrel | Cloplatic | Nefazan | Pidogrel | Plagrel | Plavix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azagrel | Bioplatelet | Bisfar | Cirgrel | Clodovas | Clodroplus | Clopaspen | Clopid | Clopidel | Clopidex | Clopidogrel | Clopidrogrel | Clopilet | Clopival | Cloptan | Clovaz | Gridokline | Instaclop | Irrigor | Ludrox | Novogrel | Pigral | Plagril | Plavix</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amnox | Clocardigel | Daklife | Dasarab | Dogrel savi | Flatovic | G5 Duratrix | Gavix | Platarex | Ridlor | Sagason | Tunadimet | Usarclopi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arrow Clopidogrel | Aviolix | Clopidogrel | Clopidogrel unicorn | Clopidogrel winthrop | Clopivas | Clopiwin | Closolve | Clovexa | Deplatt | Mistro | Pharma Dynamics Clopidogrel | Plagrol | Plavix | Spec clopidogrel | Zyklot</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Antiplar | Cadigrel | Ceruvin | Clopikind | Cloptaz | Deplatt | Instaclop | Larvin | Plasep</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bidogrel | Deplatt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24678937">
<a name="24678937"></a>Adams DH, Popma JJ, Reardon MJ, et al; US CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. <i>N Engl J Med</i>. 2014;370(19):1790-1798. doi: 10.1056/NEJMoa1400590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/24678937/pubmed" id="24678937" target="_blank">24678937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315275">
<a name="22315275"></a>Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e669S-e690S. doi: 10.1378/chest.11-2307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22315275/pubmed" id="22315275" target="_blank">22315275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249585">
<a name="25249585"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2014;130(25):e433-e434]. <i>Circulation</i>. 2014;130(25):e344-e426. doi: 10.1161/CIR.0000000000000134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25249585/pubmed" id="25249585" target="_blank">25249585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084738">
<a name="29084738"></a>Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y<sub>12</sub> receptor-inhibiting therapies. <i>Circulation</i>. 2017;136(20):1955-1975. doi:10.1161/CIRCULATIONAHA.117.031164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29084738/pubmed" id="29084738" target="_blank">29084738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22091257">
<a name="22091257"></a>Azarm T, Sohrabi A, Mohajer H, Azarm A. Thrombotic thrombocytopenic purpura associated with clopidogrel: a case report and review of the literature. <i>J Res Med Sci</i>. 2011;16(3):353-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22091257/pubmed" id="22091257" target="_blank">22091257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30119955">
<a name="30119955"></a>Báez-Ferrer N, Grande-Flecha AS, Domínguez-Rodríguez A. Stevens-Johnson syndrome and treatment with clopidogrel. <i>Rev Esp Cardiol (Engl Ed)</i>. 2019;72(8):674. doi:10.1016/j.rec.2018.06.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30119955/pubmed" id="30119955" target="_blank">30119955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22093501">
<a name="22093501"></a>Basra SS, Tsai P, and Lakkis NM. Safety and Efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. <i>J Am Coll Cardiol</i>. 2011;58(22):2263-2269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22093501/pubmed" id="22093501" target="_blank">22093501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22584549">
<a name="22584549"></a>Bauer ME, Bauer ST, Rabbani AB, et al, "Peripartum Management of Dual Antiplatelet Therapy and Neuraxial Labor Analgesia After Bare Metal Stent Insertion for Acute Myocardial Infarction," <i>Anesth Analg</i>, 2012, 115(3):613-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22584549/pubmed" id="22584549" target="_blank">22584549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beavers.1">
<a name="Beavers.1"></a>Beavers CJ, Bagai J. Avoiding being hyper about hypersensitivity: management of aspirin and P2Y12 allergic reactions. Society for Cardiovascular Angiography and Interventions. Published January 9, 2019. Accessed August 2, 2021. https://scai.org/avoiding-being-hyper-about-hypersensitivity-management-aspirin-and-p2y12-allergic-reactions
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bennett.1">
<a name="Bennett.1"></a>Bennett C, Qureshi Z. Finishing the picture: clopidogrel is indeed the most common drug associated with thrombotic thrombocytopenic purpura (TTP) in FDA databases: its mechanism, laboratory findings, clinical features, and epidemiology differ from that associated with ticlopidine [abstract 1527]. <i>Blood</i>. 2010;116(21). doi: 10.1182/blood.V116.21.1527.1527</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21282493">
<a name="21282493"></a>Brott TG, Halperin JL, Abbara S, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Stroke Association; American Association of Neuroscience Nurses; American Association of Neurological Surgeons; American College of Radiology; American Society of Neuroradiology; Congress of Neurological Surgeons; Society of Atherosclerosis Imaging and Prevention; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery; American Academy of Neurology and Society of Cardiovascular Computed Tomography. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. <i>Stroke</i>. 2011;42(8):e464-540. doi:10.1161/STR.0b013e3182112cc2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21282493/pubmed" id="21282493" target="_blank">21282493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20505173">
<a name="20505173"></a>Brott TG, Hobson RW 2nd, Howard G, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. <i>N Engl J Med</i>. 2010;363(1):11-23. doi:10.1056/NEJMoa0912321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20505173/pubmed" id="20505173" target="_blank">20505173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865376">
<a name="32865376"></a>Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. <i>N Engl J Med</i>. 2020;383(15):1447-1457. doi:10.1056/NEJMoa2017815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/32865376/pubmed" id="32865376" target="_blank">32865376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22111683">
<a name="22111683"></a>Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: clinical challenges and options for management. <i>Expert Rev Clin Pharmacol</i>. 2010;3(4):553-561. doi:10.1586/ecp.10.30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22111683/pubmed" id="22111683" target="_blank">22111683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8918275">
<a name="8918275"></a>CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). <i>Lancet</i>. 1996;348(9038):1329-1339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/8918275/pubmed" id="8918275" target="_blank">8918275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18272634">
<a name="18272634"></a>Cave AJ, Cox DW, Vicaruddin O. Loss of taste with clopidogrel. <i>Can Fam Physician</i>. 2008;54(2):195-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18272634/pubmed" id="18272634" target="_blank">18272634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21166368">
<a name="21166368"></a>Chassot PG, Marcucci C, Delabays A, Spahn DR. Perioperative antiplatelet therapy. <i>Am Fam Physician</i>. 2010;82(12):1484-1489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21166368/pubmed" id="21166368" target="_blank">21166368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21939827">
<a name="21939827"></a>Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. <i>J Am Coll Cardiol</i>. 2011;58(14):1445-1454. doi:10.1016/j.jacc.2011.06.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21939827/pubmed" id="21939827" target="_blank">21939827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25653921">
<a name="25653921"></a>Chin N, Rangamuwa K, Mariasoosai R, Carnes J, Thien F. Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation. <i>Asia Pac Allergy</i>. 2015;5(1):51-54. doi:10.5415/apallergy.2015.5.1.51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25653921/pubmed" id="25653921" target="_blank">25653921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30911446">
<a name="30911446"></a>Cohn SM, Jimenez JC, Khoury L, Perez JM, Panzo M. Inability to reverse aspirin and clopidogrel-induced platelet dysfunction with platelet infusion. <i>Cureus</i>. 2019;11(1):e3889. doi:10.7759/cureus.3889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30911446/pubmed" id="30911446" target="_blank">30911446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22392428">
<a name="22392428"></a>Coulter CJ, Montandon SV. Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias. <i>Pharmacotherapy</i>. 2012;32(2):e24-e26. doi:10.1002/PHAR.1044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22392428/pubmed" id="22392428" target="_blank">22392428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cucchiara.2022">
<a name="Cucchiara.2022"></a>Cucchiara BL, Messé SR. Long-term antithrombotic therapy for the secondary prevention of ischemic stroke. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.1">
<a name="Cutlip.1"></a>Cutlip D, Levin T. Antithrombotic therapy for elective percutaneous coronary intervention: General use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.2">
<a name="Cutlip.2"></a>Cutlip D, Lincoff AM. Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.3">
<a name="Cutlip.3"></a>Cutlip D, Nicolau JC. Long-term antiplatelet therapy after coronary artery stenting in stable patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700620">
<a name="31700620"></a>Dahal K, Mustafa U, Sharma SP, et al. Ischemic and bleeding outcomes of triple therapy in patients on chronic anticoagulation undergoing percutaneous coronary intervention: a meta-analysis of randomized trials. <i>JRSM Cardiovasc Dis</i>. 2019;8:2048004019885572. doi:10.1177/2048004019885572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31700620/pubmed" id="31700620" target="_blank">31700620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19796737">
<a name="19796737"></a>Dangas G, Mehran R, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>J Am Coll Cardiol</i>. 2009;54(15):1438-1446. doi: 10.1016/j.jacc.2009.06.021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19796737/pubmed" id="19796737" target="_blank">19796737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21841343">
<a name="21841343"></a>De Santis M, De Luca C, Mappa I, et al, "Clopidogrel Treatment During Pregnancy: A Case Report and a Review of Literature," <i>Intern Med</i>, 2011, 50(16):1769-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21841343/pubmed" id="21841343" target="_blank">21841343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23488578">
<a name="23488578"></a>Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. <i>J Card Surg</i>. 2013;28(2):109-116. doi: 10.1111/jocs.12074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23488578/pubmed" id="23488578" target="_blank">23488578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24168957">
<a name="24168957"></a>Derdeyn CP, Chimowitz MI, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. <i>Lancet</i>. 2014;383(9914):333-341. doi: 10.1016/S0140-6736(13)62038-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/24168957/pubmed" id="24168957" target="_blank">24168957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18370553">
<a name="18370553"></a>Deray G, Bagnis C, Brouard R, et al. Clopidogrel activities in patients with renal function impairment. <i>Clin Drug Investig</i>. 1998;16(4):319-328. doi:10.2165/00044011-199816040-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18370553/pubmed" id="18370553" target="_blank">18370553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12653774">
<a name="12653774"></a>Dogra S, Kanwar AJ. Clopidogrel bisulphate-induced photosensitive lichenoid eruption: first report. <i>Br J Dermatol</i>. 2003;148(3):609-610. doi:10.1046/j.1365-2133.2003.05209_17.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/12653774/pubmed" id="12653774" target="_blank">12653774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30022920">
<a name="30022920"></a>Ebi M, Inoue S, Sugiyama T, et al. A small bowel ulcer due to clopidogrel with cytomegalovirus enteritis diagnosed by capsule and double-balloon endoscopy. <i>Case Rep Gastroenterol</i>. 2018;12(2):303-310. doi:10.1159/000490096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30022920/pubmed" id="30022920" target="_blank">30022920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ehtisham.2019">
<a name="Ehtisham.2019"></a>Ehtisham A, Turan TN. Intracranial large artery atherosclerosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Export.DOR">
<a name="Export.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation. </i>2014;129(16):e463]. <i>Circulation.</i> 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291359">
<a name="16291359"></a>Finkelstein Y, Nurmohamed L, Avner M, et al, "Clopidogrel Use in Children," <i>J Pediatr</i>, 2005, 147(5):657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16291359/pubmed" id="16291359" target="_blank">16291359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29526833">
<a name="29526833"></a>Franchi F, Rollini F, Rivas Rios J, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. <i>Circulation</i>. 2018;137(23):2450-2462. doi: 10.1161/CIRCULATIONAHA.118.033983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29526833/pubmed" id="29526833" target="_blank">29526833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10678862">
<a name="10678862"></a>Garg A, Radvan J, Hopkinson N. Clopidogrel associated with acute arthritis. <i>BMJ</i>. 2000;320(7233):483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/10678862/pubmed" id="10678862" target="_blank">10678862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840333">
<a name="27840333"></a>Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Circulation</i>. 2017;135(12):e791-e792]. <i>Circulation</i>. 2017;135(12):e726-e779. doi: 10.1161/CIR.0000000000000471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/27840333/pubmed" id="27840333" target="_blank">27840333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29740754">
<a name="29740754"></a>Gimbel ME, Minderhoud SCS, Ten Berg JM. A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment. <i>Neth Heart J</i>. 2018;26(6):341-351. doi:10.1007/s12471-018-1117-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29740754/pubmed" id="29740754" target="_blank">29740754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224480">
<a name="17224480"></a>Grines CL, Bonow RO, Casey DE, et al, "AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the American College of Physicians," <i>Circulation</i>, 2007, 115(6):813-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/17224480/pubmed" id="17224480" target="_blank">17224480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22948933">
<a name="22948933"></a>Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. <i>J Gen Intern Med</i>. 2013;28(2):216-222. doi:10.1007/s11606-012-2208-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22948933/pubmed" id="22948933" target="_blank">22948933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237645">
<a name="31237645"></a>Hahn JY, Song YB, Oh JH, et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial. <i>JAMA</i>. 2019;321(24):2428-2437. doi:10.1001/jama.2019.8146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31237645/pubmed" id="31237645" target="_blank">31237645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Herbert.1993">
<a name="Herbert.1993"></a>Herbert JM, Frehel D, Vallee E, et al, "Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent," <i>Cardiovascular Drug Rev</i>, 1993, 11(2):180-98.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24318806">
<a name="24318806"></a>Huang KW, Leu HB, Luo JC, et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis. <i>Dig Dis Sci</i>. 2014;59(4):807-813. doi:10.1007/s10620-013-2973-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/24318806/pubmed" id="24318806" target="_blank">24318806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721327">
<a name="28721327"></a>Ibrahim M, Nunley DL. Two catastrophes in one patient: drug reaction with eosinophilia and systemic symptoms and toxic shock syndrome. <i>Cureus</i>. 2017;9(6):e1359. doi:10.7759/cureus.1359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/28721327/pubmed" id="28721327" target="_blank">28721327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32110414">
<a name="32110414"></a>Inagaki Y, Tachibana K, Inoue Y, Kasai T, Inoue Y. Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation. <i>Respirol Case Rep</i>. 2020;8(3):e00541. doi:10.1002/rcr2.541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/32110414/pubmed" id="32110414" target="_blank">32110414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23111862">
<a name="23111862"></a>Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). <i>Semin Thromb Hemost</i>. 2012;38(8):845-853. doi:10.1055/s-0032-1328894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23111862/pubmed" id="23111862" target="_blank">23111862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jim.1">
<a name="Jim.1"></a>Jim J, Fairman RM. Percutaneous carotid artery stenting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 18, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jim.2">
<a name="Jim.2"></a>Jim J. Transcarotid artery revascularization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 18, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29766750">
<a name="29766750"></a>Johnston SC, Easton JD, Farrant M, et al; Clinical Research Collaboration; Neurological Emergencies Treatment Trials Network; POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. <i>N Engl J Med</i>. 2018;379(3):215-225. doi: 10.1056/NEJMoa1800410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29766750/pubmed" id="29766750" target="_blank">29766750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31238700">
<a name="31238700"></a>Johnston SC, Elm JJ, Easton JD, et al. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke. <i>Circulation</i>. 2019;140(8):658-664. doi:10.1161/CIRCULATIONAHA.119.040713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31238700/pubmed" id="31238700" target="_blank">31238700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29121410">
<a name="29121410"></a>Kalich BA, Allender JE, Hollis IB. Medication management of patients undergoing transcatheter aortic valve replacement. <i>Pharmacotherapy</i>. 2018;38(1):122-138. doi: 10.1002/phar.2056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29121410/pubmed" id="29121410" target="_blank">29121410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23428007">
<a name="23428007"></a>Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. <i>JACC Cardiovasc Interv</i>. 2013;6(2):158-165. doi: 10.1016/j.jcin.2012.09.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23428007/pubmed" id="23428007" target="_blank">23428007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26684918">
<a name="26684918"></a>Khodor S, Castro M, McNamara C, Chaulagain CP. Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. <i>Hematol Oncol Stem Cell Ther</i>. 2016;9(2):76-79. doi:10.1016/j.hemonc.2015.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/26684918/pubmed" id="26684918" target="_blank">26684918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34024117">
<a name="34024117"></a>Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/34024117/pubmed" id="34024117" target="_blank">34024117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25679302">
<a name="25679302"></a>Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25679302/pubmed" id="25679302" target="_blank">25679302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609071">
<a name="31609071"></a>Kuno T, Takagi H, Sugiyama T, et al. Antithrombotic strategies after transcatheter aortic valve implantation: insights from a network meta-analysis [published online October 14, 2019]. <i>Catheter Cardiovasc Interv</i>. doi:10.1002/ccd.28498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31609071/pubmed" id="31609071" target="_blank">31609071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26506270">
<a name="26506270"></a>Kwolek CJ, Jaff MR, Leal JI, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. <i>J Vasc Surg</i>. 2015;62(5):1227-1234. doi:10.1016/j.jvs.2015.04.460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/26506270/pubmed" id="26506270" target="_blank">26506270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315273">
<a name="22315273"></a>Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 Suppl):e601S-e636S. doi:10.1378/chest.11-2302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22315273/pubmed" id="22315273" target="_blank">22315273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20961243">
<a name="20961243"></a>Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. <i>N Engl J Med</i>. 2010;363(17):1597-1607. doi:10.1056/NEJMoa1008232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20961243/pubmed" id="20961243" target="_blank">20961243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27040324">
<a name="27040324"></a>Leon MB, Smith CR, Mack MJ, et al; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. <i>N Engl J Med</i>. 2016;374(17):1609-1620. doi: 10.1056/NEJMoa1514616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/27040324/pubmed" id="27040324" target="_blank">27040324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levin.2021">
<a name="Levin.2021"></a>Levin T, Cutlip D. Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i>. 2011;124(23):e574-e651. doi:10.1161/CIR.0b013e31823ba622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27036918">
<a name="27036918"></a>Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2016;68(10):1082-1115. doi: 10.1016/j.jacc.2016.03.513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/27036918/pubmed" id="27036918" target="_blank">27036918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18195173">
<a name="18195173"></a>Li JS, Yow E, Berezny KY, et al, "Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial," <i>Circulation</i>, 2008, 117(4):553-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18195173/pubmed" id="18195173" target="_blank">18195173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622955">
<a name="28622955"></a>Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. <i>Lancet</i>. 2017;390(10093):490-499. doi:10.1016/S0140-6736(17)30770-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/28622955/pubmed" id="28622955" target="_blank">28622955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lincoff.2020">
<a name="Lincoff.2020"></a>Lincoff AM, Cutlip D. Acute ST-elevation myocardial infarction: Antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20941557">
<a name="20941557"></a>Lokhandwala J, Best PJ, Henry Y, Berger PB. Allergic reactions to clopidogrel and cross-reactivity to other agents. <i>Curr Allergy Asthma Rep</i>. 2011;11(1):52-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20941557/pubmed" id="20941557" target="_blank">20941557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22942294">
<a name="22942294"></a>Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypass occlusion After off-pump procedures) randomised study. <i>Heart</i>. 2012;98(23):1710-1715. doi:10.1136/heartjnl-2012-302449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22942294/pubmed" id="22942294" target="_blank">22942294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19367789">
<a name="19367789"></a>Matthews KE, Hameed B, Jawed S. Acute severe pancytopenia associated with clopidogrel. <i>Br J Hosp Med (Lond)</i>. 2009;70(1):52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19367789/pubmed" id="19367789" target="_blank">19367789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399658">
<a name="25399658"></a>Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med</i>. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25399658/pubmed" id="25399658" target="_blank">25399658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20817281">
<a name="20817281"></a>Mehta SR, Tanguay JF, Eikelboom JW, et al; CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet</i>. 2010;376(9748):1233-1243. doi:10.1016/S0140-6736(10)61088-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20817281/pubmed" id="20817281" target="_blank">20817281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11520521">
<a name="11520521"></a>Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet</i>. 2001;358(9281):527-533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/11520521/pubmed" id="11520521" target="_blank">11520521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16911296">
<a name="16911296"></a>Meissner M, Beier C, Wolter M, Kaufmann R, Gille J. Suberythrodermic pustular psoriasis induced by clopidogrel. <i>Br J Dermatol</i>. 2006;155(3):630-631. doi:10.1111/j.1365-2133.2006.07380.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16911296/pubmed" id="16911296" target="_blank">16911296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e737S-e801S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21637401">
<a name="21637401"></a>Monteiro PH, Dos Santos Pinheiro L, Alvoeiro L, Lucas M, Victorino RM. Clopidogrel-induced liver failure. <i>JRSM Short Rep</i>. 2011;2(5):40. doi:10.1258/shorts.2011.010111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21637401/pubmed" id="21637401" target="_blank">21637401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22425260">
<a name="22425260"></a>Muller C, Caillard S, Jesel L, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. <i>Am J Kidney Dis</i>. 2012;59(6):777-785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22425260/pubmed" id="22425260" target="_blank">22425260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21768844">
<a name="21768844"></a>Myers GR, Hoffman MK, and Marshall ES, "Clopidogrel Use Throughout Pregnancy in a Patient With a Drug-Eluting Coronary Stent," <i>Obstet Gynecol</i>, 2011, 118(2 Pt 2):432-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21768844/pubmed" id="21768844" target="_blank">21768844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29538453">
<a name="29538453"></a>Nam YH, Brensinger CM, Bilker WB, et al. Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: a retrospective cohort study [published correction appears in <i>PLoS One</i>. 2018;13(7):e0200982]. <i>PLoS One</i>. 2018;13(3):e0193800. doi:10.1371/journal.pone.0193800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29538453/pubmed" id="29538453" target="_blank">29538453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CLARINET.1">
<a name="CLARINET.1"></a>NCT00396877, “Efficacy and Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation (CLARINET),” Unpublished data. Available at <a href="https://clinicaltrials.gov/ct2/show/results/NCT00396877?term=clopidogrel&amp;amp;age=0&amp;amp;rank=3&amp;amp;sect=X0125#all" target="_blank">http://clinicaltrials.gov/ct2/show/results/NCT00396877?term=clopidogrel&amp;age=0&amp;rank=3&amp;sect=X0125#all</a>. Accessed April 14, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12940930">
<a name="12940930"></a>Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. <i>Aliment Pharmacol Ther</i>. 2003;18(4):443-449. doi:10.1046/j.1365-2036.2003.01693.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/12940930/pubmed" id="12940930" target="_blank">12940930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33202084">
<a name="33202084"></a>Nguyen KA, Eadon MT, Yoo R, et al. Risk factors for bleeding and clinical ineffectiveness associated with clopidogrel therapy: a comprehensive meta-analysis. <i>Clin Transl Sci</i>. 2021;14(2):645-655. doi:10.1111/cts.12926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/33202084/pubmed" id="33202084" target="_blank">33202084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33202084">
<a name="33202084"></a>O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub> inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Circulation</i>. 2020;142(6):538-545. doi:10.1161/CIRCULATIONAHA.120.046251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/33202084/pubmed" id="33202084" target="_blank">33202084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Filho.2020">
<a name="Filho.2020"></a>Oliveira-Filho J, Mullen MT. Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27722029">
<a name="27722029"></a>Osuagwu FC, Parashar S, Amalraj B, Tinklepaugh M, Dillon J, Bradley RH. Clopidogrel-induced auditory and visual hallucinations. <i>Prim Care Companion CNS Disord</i>. 2016;18(3):10.4088/PCC.15l01894. doi:10.4088/PCC.15l01894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/27722029/pubmed" id="27722029" target="_blank">27722029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063810">
<a name="28063810"></a>Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents [published correction appears in <i>J Am Coll Cardiol</i>. 2017;69(10):1362]. <i>J Am Coll Cardiol</i>. 2017;69(10):1313-1346. doi: 10.1016/j.jacc.2016.12.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/28063810/pubmed" id="28063810" target="_blank">28063810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18225971">
<a name="18225971"></a>Owen P, Garner J, Hergott L, Page RL 2nd. Clopidogrel desensitization: case report and review of published protocols. <i>Pharmacotherapy</i>. 2008;28(2):259-270. doi:10.1592/phco.28.2.259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18225971/pubmed" id="18225971" target="_blank">18225971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31424481">
<a name="31424481"></a>Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials [published correction appears in <i>JAMA Neurol</i>. 2019]. <i>JAMA Neurol</i>. 2019;76(12):1466-1473. doi:10.1001/jamaneurol.2019.2531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31424481/pubmed" id="31424481" target="_blank">31424481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21958886">
<a name="21958886"></a>Patti G, Bárczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>J Am Coll Cardiol</i>. 2011;58(15),1592-1599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21958886/pubmed" id="21958886" target="_blank">21958886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14504182">
<a name="14504182"></a>Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>Circulation</i>. 2003;108(14):1682-1687. doi:10.1161/01.CIR.0000091201.39590.CB<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/14504182/pubmed" id="14504182" target="_blank">14504182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14651737">
<a name="14651737"></a>Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. <i>Br J Clin Pharmacol</i>. 2003;56(5):583. doi:10.1046/j.0306-5251.2003.01918.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/14651737/pubmed" id="14651737" target="_blank">14651737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23846525">
<a name="23846525"></a>Pisapia R, Abdeddaim A, Mariano A, et al. Acute hepatitis associated with clopidogrel: a case report and review of the literature. <i>Am J Ther</i>. 2015;22(1):e8-e13. doi:10.1097/MJT.0b013e318293b0d6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23846525/pubmed" id="23846525" target="_blank">23846525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Plavix.1">
<a name="Plavix.1"></a>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Plavix.2">
<a name="Plavix.2"></a>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Plavix.3">
<a name="Plavix.3"></a>Plavix (clopidogrel) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29367334">
<a name="29367334"></a>Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29367334/pubmed" id="29367334" target="_blank">29367334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29264578">
<a name="29264578"></a>Rajpal A, Kassem LS, Moscoso-Cordero M, Arafah BM. Clopidogrel-induced insulin autoimmune syndrome: a newly recognized cause of hypoglycemia in a patient without diabetes. <i>J Endocr Soc</i>. 2017;1(9):1217-1223. doi:10.1210/js.2017-00316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/29264578/pubmed" id="29264578" target="_blank">29264578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28304219">
<a name="28304219"></a>Reardon MJ, Van Mieghem NM, Popma JJ, et al; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. <i>N Engl J Med</i>. 2017;376(14):1321-1331. doi: 10.1056/NEJMoa1700456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/28304219/pubmed" id="28304219" target="_blank">28304219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26623244">
<a name="26623244"></a>Rubano JA, Chen K, Sullivan B, Vosswinkel JA, Jawa RS. Clopidogrel-associated thrombotic thrombocytopenic purpura following endovascular treatment of spontaneous carotid artery dissection. <i>J Neurol Surg Rep</i>. 2015;76(2):e287-e290. doi:10.1055/s-0035-1566127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/26623244/pubmed" id="26623244" target="_blank">26623244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15758000">
<a name="15758000"></a>Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. <i>N Engl J Med</i>. 2005a;352(12):1179-1189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/15758000/pubmed" id="15758000" target="_blank">15758000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143698">
<a name="16143698"></a>Sabatine MS, Cannon CP, Gibson CM, et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. <i>JAMA</i>. 2005b;294(10):1224-1232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16143698/pubmed" id="16143698" target="_blank">16143698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15561695">
<a name="15561695"></a>Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. <i>Hematology Am Soc Hematol Educ Program</i>. 2004;407-423. doi:10.1182/asheducation-2004.1.407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/15561695/pubmed" id="15561695" target="_blank">15561695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20440227">
<a name="20440227"></a>Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. <i>Pharmacogenet Genomics</i>. 2010;20(7):463-465. doi:10.1097/FPC.0b013e3283385420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20440227/pubmed" id="20440227" target="_blank">20440227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23698643">
<a name="23698643"></a>Scott SA, Sangkuhl K, Stein CM, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. <i>Clin Pharmacol Ther</i>. 2013;94(3):317-323. doi: 10.1038/clpt.2013.105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23698643/pubmed" id="23698643" target="_blank">23698643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23329717">
<a name="23329717"></a>Shetty RK, Madken M, Naha K, Vivek G. Leucocytoclastic vasculitis as a late complication of clopidogrel therapy. <i>BMJ Case Rep</i>. 2013;2013:bcr2012007861. doi:10.1136/bcr-2012-007861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23329717/pubmed" id="23329717" target="_blank">23329717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23694867">
<a name="23694867"></a>Short S, Kram B, Taylor S, Cheng J, Ali K, Vasquez D. Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. <i>J Trauma Acute Care Surg</i>. 2013;74(6):1419-1424. doi:10.1097/TA.0b013e31828dac3e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23694867/pubmed" id="23694867" target="_blank">23694867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31202949">
<a name="31202949"></a>Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. <i>JACC Cardiovasc Interv</i>. 2019;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31202949/pubmed" id="31202949" target="_blank">31202949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20237383">
<a name="20237383"></a>Skillman KL, Caruthers RL, Johnson CE. Stability of an extemporaneously prepared clopidogrel oral suspension. <i>Am J Health Syst Pharm</i>. 2010;67(7):559-561. doi:10.2146/ajhp090163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20237383/pubmed" id="20237383" target="_blank">20237383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21639811">
<a name="21639811"></a>Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. <i>N Engl J Med</i>. 2011b;364(23):2187-2198. doi: 10.1056/NEJMoa1103510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21639811/pubmed" id="21639811" target="_blank">21639811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation.</i> 2011a;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16527995">
<a name="16527995"></a>Soman T, Rafay MF, Hune S, et al, "The Risks and Safety of Clopidogrel in Pediatric Arterial Ischemic Stroke," <i>Stroke</i>, 2006, 37(4):1120-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16527995/pubmed" id="16527995" target="_blank">16527995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12435254">
<a name="12435254"></a>Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in <i>JAMA</i>. 2003;289(8):987]. <i>JAMA</i>. 2002;288(19):2411-2420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/12435254/pubmed" id="12435254" target="_blank">12435254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280640">
<a name="30280640"></a>Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. <i>N Engl J Med</i>. 2018;379(24):2307-2318. doi:10.1056/NEJMoa1806640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30280640/pubmed" id="30280640" target="_blank">30280640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25476742">
<a name="25476742"></a>Tanios BY, Itani HS, Zimmerman DL. Clopidogrel use in end-stage kidney disease. <i>Semin Dial</i>. 2015;28(3):276-281. doi:10.1111/sdi.12338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/25476742/pubmed" id="25476742" target="_blank">25476742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34167966">
<a name="34167966"></a>Tomoda Y, Miyajima T, Nagasawa C, Awaya Y. Clopidogrel-induced pneumonia. <i>BMJ Case Rep</i>. 2021;14(6):e244564. doi:10.1136/bcr-2021-244564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/34167966/pubmed" id="34167966" target="_blank">34167966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23265750">
<a name="23265750"></a>Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. <i>J Formos Med Assoc</i>. 2012;111(12):705-710. doi:10.1016/j.jfma.2011.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23265750/pubmed" id="23265750" target="_blank">23265750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20442361">
<a name="20442361"></a>Tsai TT, Ho PM, Xu S, et al. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). <i>Circ Cardiovasc Interv</i>. 2010;3(3):230-235. doi:10.1161/CIRCINTERVENTIONS.109.919001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20442361/pubmed" id="20442361" target="_blank">20442361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Turan.2021">
<a name="Turan.2021"></a>Turan TN, Gutierrez J. Intracranial large artery atherosclerosis: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24739100">
<a name="24739100"></a>Ulman CA, Palmer DG, Trevino JJ, Olsen TG, Krishnamurthy S, Gandhi RK. Acute generalized exanthematous pustulosis induced by clopidogrel. <i>Int J Dermatol</i>. 2014;53(10):e461-e462. doi:10.1111/ijd.12508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/24739100/pubmed" id="24739100" target="_blank">24739100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20538571">
<a name="20538571"></a>Uz O, Kardeşoğlu E, Aparci M, Yiğiner O, Işilak Z, Ozmen N. Nonfatal aplastic anemia associated with clopidogrel. <i>Anadolu Kardiyol Derg</i>. 2010;10(3):291. doi:10.5152/akd.2010.075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20538571/pubmed" id="20538571" target="_blank">20538571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315274">
<a name="22315274"></a>Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;141(4):1129]. <i>Chest</i>. 2012;141(2)(suppl):e637S-e668S. doi: 10.1378/chest.11-2306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22315274/pubmed" id="22315274" target="_blank">22315274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18021870">
<a name="18021870"></a>von Tiehl KF, Price MJ, Valencia R, Ludington KJ, Teirstein PS, Simon RA. Clopidogrel desensitization after drug-eluting stent placement. <i>J Am Coll Cardiol</i>. 2007;50(21):2039-2043. doi:10.1016/j.jacc.2007.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18021870/pubmed" id="18021870" target="_blank">18021870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19717846">
<a name="19717846"></a>Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2009;361(11):1045-1057. doi: 10.1056/NEJMoa0904327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19717846/pubmed" id="19717846" target="_blank">19717846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23803136">
<a name="23803136"></a>Wang Y, Wang Y, Zhao X, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. <i>N Engl J Med</i>. 2013;369(1):11-19. doi:10.1056/NEJMoa1215340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23803136/pubmed" id="23803136" target="_blank">23803136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237644">
<a name="31237644"></a>Watanabe H, Domei T, Morimoto T, et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. <i>JAMA</i>. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/31237644/pubmed" id="31237644" target="_blank">31237644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982182">
<a name="17982182"></a>Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2007;357(20):2001-2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/17982182/pubmed" id="17982182" target="_blank">17982182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21450428">
<a name="21450428"></a>Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>J Am Coll Cardiol</i>. 2011;57(19):1920-1959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21450428/pubmed" id="21450428" target="_blank">21450428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30909763">
<a name="30909763"></a>Wu Y, Song Y, Pan Y, Gong Y, Zhou Y. High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies. <i>Scand Cardiovasc J</i>. 2019;53(2):55-61. doi:10.1080/14017431.2019.1598571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/30909763/pubmed" id="30909763" target="_blank">30909763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11519503">
<a name="11519503"></a>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in <i>N Engl J Med</i>. 2001;345(23):1716; <i>N Engl J Med</i>. 2001;345(20):1506]. <i>N Engl J Med</i>. 2001;345(7):494-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/11519503/pubmed" id="11519503" target="_blank">11519503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496900">
<a name="19496900"></a>Zafar MU, Farkouh ME, Fuster V, Chesebro JH. Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. <i>J Interv Cardiol</i>. 2009;22(4):385-389. doi:10.1111/j.1540-8183.2009.00475.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19496900/pubmed" id="19496900" target="_blank">19496900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19180126">
<a name="19180126"></a>Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). <i>Kidney Int Suppl</i>. 2009;(112):S20-S24. doi:10.1038/ki.2008.613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19180126/pubmed" id="19180126" target="_blank">19180126</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12984 Version 516.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
